Abstract
Background: Evidence is building for the utility of PARP (oral poly (ADP-ribose) polymerase) inhibitors in BRCA-mutated patients, across solid tumors. We examined the presence of somatic BRCA mutations (detected in tumor), in a population of prostate cancer patients. Comparisons between BRCA-mutated and BRCA-wildtype patients were made to determine potential combination strategies.